Ironwood Pharmaceuticals Inc. officer Tammi L. Gaskins filed a Form 144 notice on November 13, 2026, disclosing a proposed sale of 6,666 shares of Class A Common Stock with an approximate sale date of November 16, 2026.

Key Highlights

  • Filer: Tammi L. Gaskins, an officer of Ironwood Pharmaceuticals Inc.
  • Shares proposed for sale: 6,666 shares of Class A Common Stock, with an aggregate market value of $32,330.10.
  • Approximate sale date: November 16, 2026, through Etrade Securities LLC.
  • Source of shares: A Restricted Stock Unit award granted on December 11, 2024, pursuant to the issuer's Amended and Restated 2019 EIP, subject to vesting requirements; 18,000 units were acquired.
  • Purpose of sale: According to the filing, shares are "sold to cover taxes from the vesting of stock awards granted by the Issuer."
  • Shares outstanding: 165,550,760 shares of Class A Common Stock, as reported in the filing.
  • Prior three-month sales: The filing reports nothing to report for securities sold in the past three months.

Gaskins Form 144 Details: RSU Tax-Cover Sale at Ironwood Pharmaceuticals

According to the Form 144 notice filed with the SEC on November 13, 2026, Tammi L. Gaskins, identified as an officer of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), proposes to sell 6,666 shares of the company's Class A Common Stock on or around November 16, 2026. The filing lists Etrade Securities LLC, located at 3 Edison Drive, Alpharetta, Georgia 30005, as the named broker for the transaction. The aggregate market value of the proposed sale is stated as $32,330.10.

The shares proposed for sale are traced in the filing to a Restricted Stock Unit award granted on December 11, 2024, pursuant to Ironwood Pharmaceuticals' Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements. The filing indicates that 18,000 units were acquired from Ironwood Pharmaceuticals, Inc. on that date. The nature of payment is listed as "n/a," consistent with an RSU award rather than a cash purchase.

In the remarks section, the filing states that the shares are "sold to cover taxes from the vesting of stock awards granted by the Issuer." The filing further reports no securities of the issuer sold by Gaskins during the past three months. Ironwood Pharmaceuticals is headquartered at 100 Summer Street, Suite 2300, Boston, Massachusetts 02110, and the total shares outstanding are listed as 165,550,760 at the time of the notice.

What Was Disclosed

Ironwood Pharmaceuticals officer Tammi L. Gaskins filed a Form 144 on November 13, 2026, proposing a sale of 6,666 Class A Common Stock shares valued at $32,330.10, sourced from a December 2024 RSU award, to cover tax obligations from vesting.